Market Research Logo

Global Myocardial Infarction Drugs Market 2016-2020

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
    • Key buying criteria
      • Table Key buying criteria for myocardial infarction drugs
  • Disease overview
    • Types of myocardial infarction
    • Pathophysiology
      • Table Pathophysiology of myocardial infarction
    • Risk factors
      • Table Risk factors of myocardial infarction
    • Diagnosis
      • Table Diagnostic techniques for myocardial infarction
    • Management
      • Table Treatment options for myocardial infarction
  • Epidemiology and economic burden
    • Table Projected prevalence of CVDs in US
    • Burden of disease
      • Table Projected economic burden for CVDs in US
  • Pipeline analysis
    • Table Pipeline portfolio: Myocardial infarction
    • Canakinumab
    • MyoCell
    • MultiStem therapy
    • CLBS10
    • Prochymal
    • Revascor
    • CicloMulsion
    • PP-099
    • NP202
    • CAP-1002
    • Revacept
    • CSL112
  • Market landscape
    • Market overview
    • Market size and forecast
      • Table Global myocardial infarction drugs market 2015-2020 ($ billions)
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Beta blockers
    • ACE inhibitors
    • ARBs
    • Vasodilators
    • Antithrombotic agents
    • Thrombolytics
    • Glycoprotein IIb/IIIa inhibitors
    • Anti-dyslipidemic drugs
    • Calcium channel blockers
    • Analgesics
  • Market segmentation by EKG appearance
    • NSTEMI
    • STEMI
      • Table Global myocardial infarction drugs market segmentation by EKG appearance 2015
  • Market segmentation by type
    • Brand-name drugs
    • Generic drugs
      • Table Global myocardial infarction drugs market segmentation by type 2015
  • Geographical segmentation
    • Global myocardial infarction drugs market segmentation by geography 2015-2020
      • Table Global myocardial infarction drugs market segmentation by geography 2015
      • Table Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions)
    • Myocardial infarction drugs market in Americas
      • Table Myocardial infarction drugs market in Americas 2015-2020 ($ billions)
    • Myocardial infarction drugs market in EMEA
      • Table Myocardial infarction drugs market in EMEA 2015-2020 ($ billions)
    • Myocardial infarction drugs market in APAC
      • Table Myocardial infarction drugs market in APAC 2015-2020 ($ billions)
      • Table Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020
  • Market drivers
    • Increase in older population
    • Sedentary lifestyle
    • Rise in obesity
    • High prevalence of chronic conditions
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Delayed diagnosis
    • Alternative therapies
    • Extensive use of generics
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Growing awareness of disease
    • Strategic alliances
    • Increased R&D
    • Prevalent use of stent grafts
  • Vendor landscape
    • Competitive scenario
    • AstraZeneca
      • Table AstraZeneca: Business segmentation by revenue 2014
      • Table AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014
      • Table AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions)
      • Table AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions)
      • Table AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions)
      • Table AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions)
      • Table AstraZeneca: Key takeaways
    • Bayer HealthCare
      • Table Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions)
      • Table Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions)
      • Table Bayer HealthCare: Key takeaways
    • Eli Lilly
      • Table Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions)
      • Table Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions)
      • Table Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions)
      • Table Eli Lilly: Key takeaways
    • Novartis
      • Table Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions)
      • Table Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions)
      • Table Novartis: Key takeaways
    • Pfizer
      • Table Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions)
      • Table Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions)
      • Table Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
      • Table Pfizer: Key takeaways
    • Sanofi
      • Table Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions)
      • Table Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions)
      • Table Sanofi: Key takeaways
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Global Myocardial Infarction Drugs Market 2016-2020

About Myocardial Infarction Drugs

Myocardial infarction, commonly known as heart attack, is the irreparable death of the heart tissue. It occurs when blood stops flowing to a part of the myocardium (heart muscle), depriving it of oxygen and nutrients. If the coronary artery that supplies blood to the heart muscle is blocked by the formation of plaque (a substance made of fat, cholesterol, and cellular waste), the heart is starved of oxygen, a condition called cardiac ischemia, causing tissue damage. Cardiac ischemia may lead to episodes of angina or chest pain. The slow build-up of plaque on the walls of the heart narrows the blood vessels and finally blocks them. Rapid flow of lipids through the vessels may also create a tear on the walls of the vessels causing aggregation of platelets and the formation of a clot. The clot formation causes obstruction of blood supply through the vessels, leading to necrosis or the death of tissues in the heart muscle.

Technavio’s analysts forecast the global myocardial infarction drugs market to grow at a CAGR of 0.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global myocardial infarction drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of myocardial infarction.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Myocardial Infarction Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • AstraZeneca
  • Bayer HealthCare
  • Eli Lilly
  • Novartis
  • Pfizer
  • Sanofi
Other prominent vendors
  • advanceCOR
  • Armaron Bio
  • Athersys
  • BioVascular
  • BMS
  • Caladrius
  • Capricor
  • CSL Behring
  • GNT Pharma
  • GSK
  • Ischemix
  • Mesoblast
  • NeuroVive
  • Osiris Therapeutics
  • PledPharma
  • RegeneRx
  • Teva Pharmaceuticals
  • TiGenix
  • US Stem Cell
  • Ventrix
Market driver
  • Growing older population
  • For a full, detailed list, view our report
Market challenge
  • Alternative therapies
  • For a full, detailed list, view our report
Market trend
  • Growing awareness of disease
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Myocardial Infarction Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the Global Myocardial Infarction Drugs Market: AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, and Ventrix.

Commenting on the report, an analyst from Technavio’s team said: “Enhanced patient awareness is expected to lead to early disease diagnosis and treatment. The World Heart Federation along with Bupa, MOVEWeek, the European Healthy Stadia Network, and Days of the Year organizes 29th September of every year as the World Heart Day. Heart Day campaigns are organized to spread awareness about heart diseases. These campaigns are sponsored by Amgen, AstraZeneca, Bupa, Boehringer Ingelheim, Bristol-Myers Squibb, Novartis, Pfizer, and Unilever.”

According to the report, in older people, plaque accumulation in the arteries increases because of the loss of elasticity of the blood vessels. Drugmakers are realizing that an aging population will have significant impact on their business. Increasing number of patients plus lucrative pricing equals big growth for the market.

Further, the report states that the availability of effective surgical treatments and the use of catheter-based interventions pose a challenge to the growth of the market.

Companies Mentioned

AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, Sanofi, advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, Ventrix.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;